Safety of early and accelerated evidence based pharmacological therapy following acute decompensated heart failure (the fil–ahf study)
Abstract
Growing evidence supports early and intensified therapy during hospitalization for acute decompensated heart failure (ADHF) to reduce cardiovascular morbidity and mortality across the entire spectrum of ejection fraction (EF). Trials such as EMPULSE and TRANSITION have demonstrated that early initiation of empagliflozin and sacubitril/valsartan in hospitalized patients with ADHF is feasible and safe.
This study aimed to evaluate the safety and tolerability of an early and accelerated implementation of guideline–directed medical therapy, with particular focus on the four therapeutic pillars, during hospitalization for ADHF.
We retrospectively analyzed 373 consecutive patients admitted from the Emergency Department to our Cardiology Unit between August 2023 and December 2024. Utilization of the four pillars at admission and discharge was compared, along with changes in systolic blood pressure (SBP), creatinine, estimated glomerular filtration rate (eGFR), NT–proBNP, serum potassium, and hemoglobin levels.
Median age was 79 years, 59.5% were male, median BMI was 25.9, and 23.6% had diabetes. Heart failure phenotypes included HFrEF (27.6%), HFmrEF (26.8%), and HFpEF (45.6%). Use of ACEi/ARBs/ARNi increased from 58.1% at admission to 81.5% at discharge. SGLT2 inhibitor prescription rose from 22.2% to 68.1%. Beta–blocker use increased from 65.9% to 86.9%, and MRA use from 27.6% to 78.2% (Figure 1). During hospitalization, hemoglobin decreased slightly (12.9 ± 1.9 to 12.8 ± 2.0…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.